A multicentre, placebo-controlled, double-blind, crossover study conducted in general practice on 100 patients has shown clonidine to have a statistically highly significant effect in controlling the number and the severity and duration of menopausal flushes. The relatively mild side effects and the absence of potentially harmful oestrogenic effects suggest that clonidine in the dose range 25 to 75 ,ug twice daily is a useful addition or alternative to the existing therapy for this common symptom of the menopause.
Introduction
The hot flushes of the menopause can be difficult to treat. Non-oestrogenic compounds are often ineffective while oestrogens carry the small but real risk of potentially dangerous side effects. Though its underlying physiology remains obscure the condition is characterized by a peripheral vasomotor instability mainly affecting the "blush" areas with changes which are qualitatively similar, though in reverse order, to the vascular changes seen during an attack of migraine. The long-term administration of clonidine (2-(2, 6-dichlorophenylamino)-2-imidazoline hydrochloride; Dixarit) diminishes vascular reactivity (Zaimis and Hanington, 1969) ; consequently it is effective in the prophylaxis of migraine (Wilkinson, 1969; Shafer et al., 1972) . When used in considerably higher doses, as Catapres, however, it is a potent antihypertensive agent (MacDougall et al., 1970) , but with the small doses used in migraine prophylaxis no appreciable problems due to blood pressure reduction have been reported.
These facts led to a preliminary trial of clonidine in eleven unselected cases of menopausal flushing (Clayden, 1972) . The results were very encouraging in all but two patients. They were confirmed in a separate open study by Williams (1973) , who found that nine out of 13 patients benefited. During the discussion of results reported by Clayden 1973 it became evident that a carefully controlled further evaluation was needed. This paper presents the results of a placebo-controlled, double-blind, crossover, multicentre trial in general practice.
Patients and Methods
Patients were selected who suffered from menopausal flushing of sufficient severity to warrant treatment. Only those without other complicating illness and who could reasonably be expected to complete the trial were admitted. All previous medication for flushing, such as oestrogens, was stopped for at least two weeks before entry to the trial. Each patient participated for nine weeks. This period was divided into one week without treatment to obtain baseline values and to familiarize the patient with the procedure and two courses of treatment of four weeks each in which patients were randomly given the active drug or placebo as their first treatment. Neither patient nor doctor knew the order of medication.
Each attack of flushing was recorded by the patient on a diary card which was exchanged weekly. Patients were seen at nine predetermined times throughout the trial. At each visit, besides recording the number of flushes, questions were asked about the frequency, severity, and duration of attacks since the previous visit. The answers were recorded on a five-point scale from "much more" to "much less." Side effects were elicited by a simple question-for example, "Any problems with the tablets ?" No direct questioning was used unless the patient was the first to mention side effects. Blood pressures and pulse rates were recorded at each visit.
Coded sets of record cards, diary cards, and tablets were supplied for each patient. White compressed tablets containing 25 ,ug clonidine or matching placebo tablets identical in appearance and taste were used. Treatment began with one tablet twice daily and increased to a maximum of three tablets twice 9 MARCH 1974 daily depending on the effect or the presence of side effects. The patients were asked to return all unused tablets at each visit. These were counted and correlated with the number prescribed.
Out of 100 patients from 18 different practices 14 were excluded for various reasons (table I). The remaining 86 patients had a mean age of 50 4 years (range 41 to 62 years), a mean weight of 142 lb (range 98 to 190 lb) (64-6 kg; range 44-4 to 86-9 kg), and a median duration of flushing episodes before the trial of two years (range two weeks to 23 years). Forty-two patients received clonidine first. Of the 86 patients 10 did not take the prescribed number of tablets for part of the trial owing to external causes or because they misunderstood the instructions. In one of the 10 patients treatment was affected for two weeks but in the other 9 only one week was affected. The missed weeks were not included in the analysis. combined clonidine treatments is compared with placebo in fig. 2 . The questions asked at each visit on the frequency, severity, and duration of flushes, though not so reliable as a count of the number of flushes, followed a similar pattern. If the patients had been asked the questions in relation to how they were at the beginning of the trial it would have been unlikely that by the end they could have recalled their initial condition reliably. The questions were therefore asked in relation to the previous visit and the score (on a five-point scale) was a guide to whether the patient believed she was improving. For each patient the response throughout the trial was determined by cumulating the positive or negative changes in condition (difference from the "no change" score of 3) at the end of weeks 1, 2, and 4 for the first treatment and weeks 5, 6, and 8 for the second treatment. The difference for week 1 was then compared with week 5 for each patient to see which treatment gave the better result.
Similarly for weeks 2 and 6, 4 and 8 (table III) . The sign test was used to determine statistical significance (Segal, 1956) .
During the first treatment period more patients improved in all three parameters on clonidine compared with placebo. When patients received placebo as first treatment, however, clonidine still accounted for more improvements, but this did not achieve statistical significance owing partly to the placebo response and partly to some scores reaching maximum on placebo and re- maining at maximum throughout clonidine treatment so that the difference between treatments was not so distinct.
Duration of Menopause.-The duration of flushing before the trial ranged from two weeks to 23 years, which prompted a subdivision of patients into those who had had flushing for less and those who had had flushing for more than one year. Interestingly, those who had had flushing for more than one year had a far greater placebo response than those who had had flushing for less than one year. This emphasizes the psychological influences in a patient complaining of hot flushes over several years.
Blood Pressure.-There were no significant changes in the mean pulse rates and blood pressure values for either treatment (table IV) . One patient who was hypertensive at the start of the trial completed both treatment periods before beginning specific antihypertensive treatment. Dose.-As flushes ceased in only a few patients we should have expected the dose to reach three tablets twice daily in most patients, particularly those on placebo. Though this was the overall tendency more than expected did not receive the maximum dose. Fifteen patients on clonidine and 14 on placebo reached a dose of one tablet twice daily, 22 on clonidine and 21 on placebo reached a dose of two tablets twice daily, and 48 on clonidine and 50 on placebo reached a dose of three tablets twice daily. The pattern of response in each treatment group was similar for each dose but the patients who remained in the lower dose groups had proportionately fewer attacks and a milder condition at the start of the trial, which, together with the multitude of reported side effects, must have influenced the prescribing pattern.
Side Effects.-A variety of side effects were reported, which was expected considering the large functional element believed to play a part in this condition. Of 100 patients 56 reported side effects and of these 34 reported them on clonidine and 36 on placebo. The side effects were, however, mostly nonspecific and, with the possible exception of dry mouth, well distributed between the placebo and active treatment periods ( (Utian, 1973) in which no placebo response was found. There was a difference, however, in that the flushes in the patients investigated were associated with hysterectomy and bilateral oophorectomy rather than the natural menopause, which may partly accord with our finding of a lower placebo response in women who had begun flushing less than one year before the start of the trial.
Clonidine in higher doses is used for the treatment of hypertension, but despite the more labile vasculature of our patients no problems were caused by changes in blood pressure and pulse rate. All other medication, so far as possible, was stopped before admission to the trial, though in Clayden's (1972) to understand the true aetiology of menopausal flushes. It has been realized for some time that there is no clear connexion between the hormone levels in blood and urine and severity of flushes. The events at vascular level have never been fully investigated-in fact, the recent bibliography on the menopause is remarkably short. We hope that the present report will stimulate further investigation of menopausal vasomotor symptoms and of factors that precipitate them, so that they may be related more closely to other vasomotor disorders.
We may state in conclusion that clonidine, in doses similar to those used for migraine prophylaxis, seems a useful and safe alternative or even addition to other treatments for hot flushes and that it has no important side effects.
